Kexing Biopharm (688136.SH): Human Interferon α-1b Inhalation Solution Included in Breakthrough Therapy Designation List

Stock News2025-09-23

Kexing Biopharm Co.,Ltd. (688136.SH) announced that the human interferon α-1b inhalation solution, independently developed by its wholly-owned subsidiary Shenzhen Kexing Pharmaceutical Co., Ltd. ("Shenzhen Kexing"), has been included in the breakthrough therapy designation list by the Center for Drug Evaluation of the National Medical Products Administration. The public notice has recently been completed.

Interferon (IFN) is a class of proteins with broad-spectrum antiviral, antitumor, and immunomodulatory properties, serving as a key component of the body's natural immune system. The human interferon α-1b inhalation solution represents another major breakthrough for the company in the antiviral field. This pediatric-specific drug is administered through nebulization, allowing the active ingredient to directly reach the affected area for faster onset of action. Compared to injectable formulations, pediatric patients can avoid injection-related pain, resulting in higher acceptance and improved safety profile.

The company's human interferon α-1b inhalation solution is indicated for pediatric respiratory syncytial virus lower respiratory tract infections, including pneumonia and bronchiolitis.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1144922497?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-23 16:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144922497","market":"hk","top_or_hot":-1,"title":"Kexing Biopharm (688136.SH): Human Interferon α-1b Inhalation Solution Included in Breakthrough Therapy Designation List","media":"Stock News","content":"<p>Kexing Biopharm Co.,Ltd. (688136.SH) announced that the human interferon α-1b inhalation solution, independently developed by its wholly-owned subsidiary Shenzhen Kexing Pharmaceutical Co., Ltd. (\"Shenzhen Kexing\"), has been included in the breakthrough therapy designation list by the Center for Drug Evaluation of the National Medical Products Administration. The public notice has recently been completed.</p>\n<p>Interferon (IFN) is a class of proteins with broad-spectrum antiviral, antitumor, and immunomodulatory properties, serving as a key component of the body's natural immune system. The human interferon α-1b inhalation solution represents another major breakthrough for the company in the antiviral field. This pediatric-specific drug is administered through nebulization, allowing the active ingredient to directly reach the affected area for faster onset of action. Compared to injectable formulations, pediatric patients can avoid injection-related pain, resulting in higher acceptance and improved safety profile.</p>\n<p>The company's human interferon α-1b inhalation solution is indicated for pediatric respiratory syncytial virus lower respiratory tract infections, including pneumonia and bronchiolitis.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kexing Biopharm (688136.SH): Human Interferon α-1b Inhalation Solution Included in Breakthrough Therapy Designation List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKexing Biopharm (688136.SH): Human Interferon α-1b Inhalation Solution Included in Breakthrough Therapy Designation List\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-23 16:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Kexing Biopharm Co.,Ltd. (688136.SH) announced that the human interferon α-1b inhalation solution, independently developed by its wholly-owned subsidiary Shenzhen Kexing Pharmaceutical Co., Ltd. (\"Shenzhen Kexing\"), has been included in the breakthrough therapy designation list by the Center for Drug Evaluation of the National Medical Products Administration. The public notice has recently been completed.</p>\n<p>Interferon (IFN) is a class of proteins with broad-spectrum antiviral, antitumor, and immunomodulatory properties, serving as a key component of the body's natural immune system. The human interferon α-1b inhalation solution represents another major breakthrough for the company in the antiviral field. This pediatric-specific drug is administered through nebulization, allowing the active ingredient to directly reach the affected area for faster onset of action. Compared to injectable formulations, pediatric patients can avoid injection-related pain, resulting in higher acceptance and improved safety profile.</p>\n<p>The company's human interferon α-1b inhalation solution is indicated for pediatric respiratory syncytial virus lower respiratory tract infections, including pneumonia and bronchiolitis.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1144922497","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144922497","pubTimestamp":1758614922,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Kexing Biopharm Co.,Ltd. (688136.SH) announced that the human interferon α-1b inhalation solution, independently developed by its wholly-owned subsidiary Shenzhen Kexing Pharmaceutical Co., Ltd....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688136":"科兴制药","BK0239":"医药制造"},"translate_title":"科兴生物（688136.SH）：人干扰素α-1b吸入溶液纳入突破性疗法认定名单","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688136":1},"content_text":"Kexing Biopharm Co.,Ltd. (688136.SH) announced that the human interferon α-1b inhalation solution, independently developed by its wholly-owned subsidiary Shenzhen Kexing Pharmaceutical Co., Ltd. (\"Shenzhen Kexing\"), has been included in the breakthrough therapy designation list by the Center for Drug Evaluation of the National Medical Products Administration. The public notice has recently been completed.\nInterferon (IFN) is a class of proteins with broad-spectrum antiviral, antitumor, and immunomodulatory properties, serving as a key component of the body's natural immune system. The human interferon α-1b inhalation solution represents another major breakthrough for the company in the antiviral field. This pediatric-specific drug is administered through nebulization, allowing the active ingredient to directly reach the affected area for faster onset of action. Compared to injectable formulations, pediatric patients can avoid injection-related pain, resulting in higher acceptance and improved safety profile.\nThe company's human interferon α-1b inhalation solution is indicated for pediatric respiratory syncytial virus lower respiratory tract infections, including pneumonia and bronchiolitis.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1144922497","isCrawlerRequest":true}